Deals channel feed

Roche bets again on Io­n­is in Hunt­ing­ton’s, Alzheimer's

2 days ago

Ex­clu­sive: Pfiz­er, Gink­go sign R&D deal worth up to $331M to de­vel­op RNA drugs

2 days ago

In­ter­cept to sell in $800M cash buy­out af­ter sec­ond NASH re­jec­tion sank hopes

3 days ago

Take­da strikes $500M+ deal for Cal­i­for­nia biotech's ALS pro­gram

4 days ago
Pharma

No­vo signs up for near­ly a dozen car­diometa­bol­ic pro­grams out of Va­lo Health

4 days ago

Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

5 days ago
R&D
Pharma

Six years af­ter with­draw­ing IPO, Abpro takes SPAC route to Nas­daq — with plans to take HER2 bis­pe­cif­ic to clin­ic

Last week

Af­ter Ver­sa­nis suc­cess, Adi­tum launch­es Celex­or Bio with au­toim­mune drug from Ace­lyrin part­ner In­ma­gene

Last week
Financing
Startups

Genen­tech gets gluey, pay­ing $47M up­front to Ori­o­n­is for de­grad­er dis­cov­ery deal

Last week

Benev­o­len­tAI, Ex­sci­en­tia on the come­back trail af­ter se­cur­ing sep­a­rate AI drug dis­cov­ery deals with Mer­ck KGaA

Last week
AI

Up­dat­ed: Roche’s Genen­tech wades in­to ra­dio­phar­ma­ceu­ti­cals with Pep­tiDream al­liance, $40M up­front

Last week

No­var­tis hands back PD-1 in­hibitor to BeiGene af­ter reg­u­la­to­ry hur­dles

Last week
R&D
FDA+

Ab­cam finds founder’s op­po­si­tion to Dana­her deal ‘sur­pris­ing,’ say­ing he's sow­ing 'con­fu­sion for share­hold­er­s'

2 weeks ago
People

Ab­b­Vie turns its back on Har­poon’s BC­MA-tar­get­ing mul­ti­ple myelo­ma drug

3 weeks ago
R&D

Roy­al­ty Phar­ma ex­ecs shed light on strat­e­gy be­hind their first gene ther­a­py deal

3 weeks ago
Cell/Gene Tx

Ex­elix­is li­cens­es small mol­e­cule from In­sil­i­co for $80M up­front; Ver­tex buys GPCR from Septer­na

3 weeks ago

Mod­er­na strikes $1.8B can­cer re­search deal with Im­mat­ics 

3 weeks ago

Verge Ge­nomics teams up with As­traZeneca in drug dis­cov­ery deal

3 weeks ago

Ot­su­ka pens AAV deal with Shape Ther­a­peu­tics for eye gene ther­a­pies

4 weeks ago
Cell/Gene Tx

Seagen teams up with pro­tein degra­da­tion spe­cial­ist to make a new kind of an­ti­body con­ju­gate, pay­ing $60M up­front

4 weeks ago

Kriya Ther­a­peu­tics buys sci­en­tif­ic ad­vi­sor’s NASH gene ther­a­py com­pa­ny

4 weeks ago
Pharma

Amid aproci­ten­tan’s reg­u­la­to­ry re­view, Idor­sia is buy­ing back the hy­per­ten­sion drug from J&J in $350M deal

4 weeks ago
FDA+

Nestlé parts with peanut al­ler­gy treat­ment Pal­forzia

4 weeks ago
Pharma

Bio­gen se­cures $1.5B loan to fund Rea­ta buy­out, with three-year re­pay­ment sched­ule baked in

4 weeks ago
Financing
1234 Next page Last page
A service from the Financial Times